PreciseDx – Morphology Feature Array (MFA) as a Risk Assessment Platform for Breast Cancer Treatment (AI PHI Affinity Group)

Thank you for coming!

The recording for this meeting is available below:

–

Topic

Morphology Feature Array (MFA) as a Risk Assessment Platform for Breast Cancer Treatment

In our presentation we cover the development and practical application of a digital pathology, AI-derived digital laboratory-developed test (LDT) to phenotype, grade, and prognosticate early-stage invasive breast cancer — ultimately to support patient treatment planning and management decisions.

Speakers

Michael Donovan, MD, Ph.D.

Co-Founder and Chief Medical Officer

Dr. Donovan is a co-founder of PreciseDx, and currently serves as Vice-chair and Professor of Translational Research in the Department of Pathology at the University of Miami. In addition to a previous academic career at Harvard Medical School and Boston Children’s Hospital, Dr. Donovan has over 20 years of experience in the biotechnology industry, serving in various senior management roles at Millennium Pharmaceuticals and Incyte Pharmaceuticals.
Most recently, he has served as Chief Medical Officer of Renalytix, Chief Clinical Officer of Vigilant Biosciences, Inc., Chief Medical Officer of MetaStat, Inc., and Chief Medical Officer of Exosome Diagnostics, Inc. Dr. Donovan earned his Bachelor of Science degree in Zoology, a Master of Science degree in Endocrinology, and a Ph.D. in Cell and Developmental Biology from Rutgers University. He received his medical degree from the Rutgers New Jersey Medical School.

Gerardo Fernandez, MD

Co-Founder and Chief Scientific Officer

Dr. Fernandez is a co-founder and currently Chief Scientific Officer of PreciseDx, in addition to his position as Adjunct Associate Professor in the Department of Pathology, Molecular and Cell-Based Medicine at the Icahn School of Medicine at the Mount Sinai Health System. He received his medical degree from Drexel University College of Medicine and completed his residency in anatomic and clinical pathology as well as fellowships in surgical pathology and cytopathology from New York University School of Medicine.
Dr. Fernandez has spent the last seven years as Associate Professor at Mount Sinai building and developing the PreciseDx team and platform. Before that, he was in industry as the Medical Director for Roche Tissue Diagnostics’ (Ventana) Digital Pathology group, Vice President for Pathology and Research and Development at Aureon Biosciences, and a Staff Pathologist at Genzyme Genetics, where he specialized in oncologic pathology and tissue biomarkers.
–

Artificial Intelligence in Cancer Research – AI PHI Affinity Group

(First Friday of each month)

This group was formed to discuss the current trends and applications of artificial intelligence in cancer research and clinical practice. The group brings together AI researchers in a variety of fields (computer science, engineering, nutrition, epidemiology radiology, etc) with clinicians and advocates. Students, trainees and faculty with any or no background in AI are encouraged to attend. The goal is to foster collaborative interactions to solve problems in cancer that were thought to be unsolvable a decade ago before the broad use of deep learning and AI in medicine.

Contact: Dr. John Shepherd at johnshep@hawaii.edu or Peter Washington at pyw@hawaii.edu